Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumor with a poor prognosis, characterized by a high recurrence and mortality rate. The challenges in treating GBM include the blood-brain barrier (BBB), which hinders drug penetration into the central nervous system (CNS), and resistance to the first-line drug, temozolomide (TMZ). Therefore, research into new treatments that overcome these …